Results 1 to 10 of about 49,721 (234)
Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety [PDF]
Biomedicines, 2023 Taxanes (paclitaxel and docetaxel) are one of the most useful classes of anticancer drugs. Taxanes are highly hydrophobic; therefore, these drugs must be dissolved in organic solvents (polysorbate or Cremophor EL), which contribute to their toxicities ...
Md Sazzad Hassan +2 more
exaly +4 more sources
First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report [PDF]
Case Reports in Oncology, 2017 Thymic carcinomas are rare malignant tumors, located in the anterior mediastinum. For the treatment of these carcinomas, several chemotherapy regimens have been suggested, including carboplatin plus paclitaxel.
Kunihiko Funaishi +7 more
doaj +4 more sources
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel [PDF]
Case Reports in Oncology, 2023 We present a rare phenomenon of a soft tumor hanging on the woman’s left upper arm that underwent necrosis from the distal aspect during chemotherapy for pancreatic cancer. The benign tumor, pedunculated lipofibroma, originally had normal color for 10 years and then became necrotic when she was treated with gemcitabine and nab-paclitaxel.
Hiraku Kokubu +3 more
core +5 more sources
Therapeutic Advances in Medical Oncology, 2023 Background: Most patients with small-cell lung cancer (SCLC) experience disease progression after first-line chemotherapy. Notably, nab-paclitaxel monotherapy has antitumor activity in relapsed SCLC.
Rui Wan +5 more
doaj +3 more sources
Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas
Frontiers in Oncology, 2022 Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently
Zhichao Tian, Weitao Yao
doaj +1 more source
Frontiers in Oncology, 2021 Angiographically silent cystoid macular edema (CME) is a rare complication from nab-paclitaxel. Here we report a 45-year-old woman with breast cancer who developed CME after several months of treatment with albumin-bound paclitaxel (nab-paclitaxel).
Suna Ye +8 more
doaj +1 more source
BMC Cancer, 2022 Background Triple negative breast cancer (TNBC) is clinically aggressive breast cancer with a poor prognosis. Approximately 20% of TNBC has been found to express programmed death ligand 1 (PD-L1), making it a potential therapeutic target.
K. Sharmni Vishnu +3 more
doaj +1 more source
Macular Cystoid Edema Induced by Nab-Paclitaxel
Acta Médica Portuguesa, 2022 A 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively.
Sara Alves Pereira +3 more
openaire +4 more sources
BMC Cancer, 2021 Background Although various clinical trials and real-life studies have tried to explore the value of nab-paclitaxel mono-chemotherapy for metastatic breast cancer (MBC), the safety and efficacy of nab-paclitaxel remain unclear which need to be ...
Haili Lu +8 more
doaj +1 more source
Journal of Pharmacological Sciences, 2011 .: Nanoparticle albumin–bound paclitaxel (nab-paclitaxel) is delivered to tumors and increases antitumor activity compared with solvent-based paclitaxel.
Yuji Yamashita +5 more
doaj +1 more source